Another product based on Dr. Ullrich's work is the anti-cancer drug Herceptin (trastuzumab). In the mid-1980s, Dr. Ullrich and collaborators discovered that 30 percent of breast cancer patients overexpress the HER2 gene, which is a gene involved in the development of invasive cancers. This was the basis for the development of a monoclonal antibody that inhibits HER2 production, known as Herceptin, which been used since the late 1990s to treat patients with metastatic breast cancer. It has been shown to improve overall survival and prevents tumor recurrence in many women.
Dr. Ullrich received his primary degree in biochemistry at the University of Tubingen, Germany, and his Ph.D. from the University of Heidelberg in Molecular Genetics in 1975. He worked as a senior scientist at Genentech in San Francisco from 1978 to 1988. Since then, he has been Managing Director of the Max Plank Institute of Biochemistry.
He also received the 2010 Wolf Prize for research on human proto-oncogenes and development of novel cancer therapies.
After the award and keynote speech are delivered, Marc S. Williams, M.D., Director of the Genomic Medicine Institute, Geisinger Health System, and David Nash, M.D., MBA, Dean of Jefferson School of Population Health, will address the symposium. A poster session and reception hosted by the Chairman of the symposium planning committee, Stephen C. Peiper, M.D., Peter A. Herbut Professor and Chair, in the Department of Pathology, Anatomy and Cell Biology at Jefferson, will follow.
Several researchers will speak on Nov. 30, beginning at 8:30 a.m., at the Bluemle Life Sciences Building, 233 S 10th Street, Room 101, on "The Role of Structural Biology in Precision Medicine." That includes John M. Pascal, Ph.D., of the Department of Biochemistry and Molecular Biology at Jefferson, Wei Yang, Ph.D., a Senior Investigator and Section Chief at the National Institute of
|Contact: Steve Graff|
Thomas Jefferson University